SynthesisZeitschrift fur Rheumatologie2017
Urinary MCP-1 as a biomarker for lupus nephritis: a meta-analysis.
Synthesis in Zeitschrift fur Rheumatologie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 57 citations in OpenAlex.
- Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial.Arthritis research & therapy · 2022Trial
- Evaluation of clinical, histological and biomarker response after initial therapy of lupus nephritis.Lupus science & medicine · 2026Article
- Kidney transplantation in Lupus Nephritis: a comprehensive review of challenges and strategies.BMC surgery · 2025Review
- Advances in Targeted Therapy for Systemic Lupus Erythematosus: Current Treatments and Novel Approaches.International journal of molecular sciences · 2025Review
- Scavenger receptors: key players in the immunological puzzle of lupus.Frontiers in lupus · 2025Article
- Application of biomarkers in the diagnosis of kidney disease.Frontiers in medicine · 2025Review
- Tissue Kallikrein-1 Suppresses Type I Interferon Responses and Reduces Depressive-Like Behavior in the MRL/lpr Lupus-Prone Mouse Model.International journal of molecular sciences · 2024Article
- Cytokines in Bladder Pain Syndrome: A Review of the Literature.International urogynecology journal · 2024Review
- Immune checkpoint inhibitors induce acute interstitial nephritis in mice with increased urinary MCP1 and PD-1 glomerular expression.Journal of translational medicine · 2024Article
- Protective effect of modified Huangqi Chifeng decoction on immunoglobulin A nephropathy through toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-kappa B signaling pathway.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024Article
- Toward Precision Medicine: Exploring the Landscape of Biomarkers in Acute Kidney Injury.Biomolecules · 2024Review
- Investigating the value of urinary biomarkers in relation to lupus nephritis histopathology: present insights and future prospects.Frontiers in pharmacology · 2024Review
- The role of inflammation in silicosis.Frontiers in pharmacology · 2024Review
- Precision medicine in systemic lupus erythematosus.Nature reviews. Rheumatology · 2023Review
- Urinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations.Brain communications · 2023Review
- Effect of add-on hydroxychloroquine therapy on serum proinflammatory cytokine levels in patients with systemic lupus erythematosus.Scientific reports · 2022Article
- Review
- Phenotypic and functional alterations of peritoneal macrophages in lupus-prone mice.Molecular biology reports · 2022Article
- Gut dysbiosis is associated with acceleration of lupus nephritis.Scientific reports · 2022Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate whether urinary monocyte chemoattractant protein-1 (MCP-1) could serve as a biomarker for lupus nephritis (LN).
methodsWe performed a meta-analysis to examine the relationship between urinary MCP-1 level and LN in three comparisons: active LN versus inactive LN, active LN versus control, and inactive LN versus control.
resultsEight studies of a total of 399 patients with LN (204 with active LN, and 195 with inactive LN) and 130 controls were available for this meta-analysis. The meta-analysis revealed that the urinary MCP-1 level was significantly higher in the active-LN group than in the inactive-LN group (standard mean difference [SMD] = 1.883, 95 % confidence interval [CI] = 0.811-2.954, p = 0.001). The meta-analysis showed that the urinary MCP-1 level was significantly higher in the active-LN group than in the control group (SMD = 3.085, 95 % CI = 1.684-4.485, p = 1.6 × 10
conclusionsThe meta-analysis demonstrated that urinary MCP-1 was significantly higher in patients with active LN than in those with inactive LN and control subjects, and the patients with inactive LN showed significantly higher urinary MCP-1 levels than the controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.